DRTSW Stock — Alpha Tau Medical Ltd.

Technicals

trend & momentum for long-term holders illustrative — not investment advice

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50/200-day averages unavailable

Institutional flow Distributing

17 of 92 funds reported for Sep 30 · net -201.6K sh shares · +3 new

Insider flow Flat

No net insider activity over 90 days

Short interest Flat

No short-interest data

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

92 holders — near 3-yr high, broad support

Price context

position in its available closing range

Range low $2 Now $4 · 63% Range high $4

vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DRTSW Alpha Tau Medical Ltd. this stock	$1.25B	—	—	—	—
VRTX Vertex Pharmaceuticals Inc	$131.39B	+15.7%	+46.2%	30.2	1.8%
MRNA Moderna, Inc.	$98.14B	+733.5%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$83.13B	+4.4%	+20.8%	20.0	2.1%
CSLLY Csl Ltd	$66.22B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

91

% held: 14.3%
Reported: 17 of 92
Top holder: LMR Partners LLP

Held Float

View

Short & Settlement

Fails to Deliver

FTD shares

208

Value: $3.1K
As of: Sep 29, 2026

View

Financials

Net income (FY)

$-42.6M

EPS diluted: $-0.53

View

Filings

SEC Filings

Latest

6-K

Filed: Oct 19, 2026
This year: 32

Alpha Tau Medical Ltd. announced FDA approval to expand its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma from 10 to 20 patients, with new endpoints and an interim analysis, and that data will be presented at the SNO 2026 Annual Meeting on November 13.

View

Proposed Sales

Value

$71.8K